Dual cyclooxygenase 2/15-lipoxygenase inhibitors constitute a valuable alternative to classical non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 (cyclooxygenase-2) inhibitors for the treatment of inflammatory diseases, as well as preventing the cancer. Indeed, these latter present diverse side effects, which are reduced or absent in dual-acting agents. In this review, COX-2 and 15-LOX (15-lipoxygenase) pathways are first described in order to highlight the therapeutic interest of designing such compounds. Various structural families of dual inhibitors are illustrated. This study discloses various structural families of dual 15-LOX/COX-2 inhibitors, thus pave the way to design potentially-active anticancer agents with balanced dual inhibition of these enzymes.

双环氧合酶2/15-脂氧合酶抑制剂是经典非甾体抗炎药 (NSAID) 和选择性 COX-2 (环氧合酶-2) 抑制剂的宝贵替代品，可用于治疗炎症性疾病以及预防癌症。事实上，后者存在多种副作用，而双作用药物会减少或不存在这些副作用。在这篇综述中，首先描述了 COX-2 和 15-LOX（15-脂氧合酶）途径，以强调设计此类化合物的治疗意义。说明了双重抑制剂的各种结构家族。这项研究公开了 15-LOX/COX-2 双抑制剂的各种结构家族，从而为设计具有这些酶的平衡双重抑制作用的潜在活性抗癌药物铺平了道路。